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Abstract
Background: The ultra-large von Willebrand factor (vWF) multimers are very active and must be degraded by ADAMTS13 for optimal activity. A se-
vere functional deficiency of ADAMTS13 has been associated with thrombotic thrombocytopenic purpura. The correct interpretation of patient vWF 
and ADAMTS13 plasma levels requires an understanding of the biological variation associated with these analytes. In the present paper, we aimed to 
determine the biological variation of ADAMTS13 and vWF in human adults.
Materials and methods: Blood samples were collected weekly from 19 healthy subjects for 5 consecutive weeks. vWF activity and antigenicity 
were determined using aggregometric and immunoturbidimetric methods. ADAMTS13 antigenicity and activity were determined by ELISA.
Results: The within-subject biological variations for vWF activity and antigenicity were 8.06% and 14.37%, respectively, while the between-subject 
biological variations were 18.5% and 22.59%, respectively. The index of individuality for vWF activity was 0.44, while vWF antigenicity was 0.64. 
Similarly, ADAMTS13 activity and antigenicity within-subject biological variations were 12.73% and 9.75%, respectively, while between-subject bio-
logical variations were 9.63% and 6.28%, respectively. The ADAMTS13 indexes of individuality were 1.32 and 1.55, respectively.
Conclusion: We report high biological variation and individuality in vWF antigenicity and activity levels. However, ADAMTS13 antigenicity and ac-
tivity displayed high biological variation, but low individuality. Thus, population-based reference intervals may be useful for monitoring ADAMTS13 
antigenicity and activity, but not for vWF, which displays high individuality. These findings should be considered when determining the reference 
interval and other clinical variables associated with ADAMTS13 and vWF levels.
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Von Willebrand factor (vWF) is a multimeric glyco-
protein that plays a major role in the primary he-
mostatic process. It is synthesized in endothelial 
cells and megakaryocytes, and secreted as ultra-
large vWF (ULvWF). vWF multimers are formed 
within the endoplasmic reticulum and secreted 
into the plasma primarily by endothelial cells 
where additional processing occurs (1). At sites of 
vascular injury, vWF induces platelet adhesion and 
aggregation (2). ULvWF are very active and must 
be processed. This occurs on the surface of en-
dothelial cells by ADAMTS13, a specific metallopro-
teinase belonging to the ADAMTS (a disintegrin 
and metalloprotease with trombospondin type 1 
repeats) family (3). ADAMTS13 regulates the size of 
vWF and is therefore crucial for its normal physio-
logical activity. In the case of ADAMTS13 deficien-
cy, vWF forms large multimers in the plasma, which 
spontaneously bind platelets and induce aggrega-
tion (4,5). A deficiency in ADAMTS13 activity has 
been implicated in the development of thrombot-
ic thrombocytopenic purpura (TTP). The congeni-
tal form of TTP is caused by a mutation in the AD-
AMTS13 gene, while autoantibodies diminish AD-
AMTS13 activity in the acquired form. The activity 
of ADAMTS13 in TTP patients is severally deficient, 
being less than 5% of normal plasma activity (6,7).
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Laboratory results are associated with a certain 
degree of variation, mainly due to analytical and 
biological variations. In automated and standard-
ized test systems, the analytical variation is often 
much lower than the biological variation. Biologi-
cal variation has two main components: within-
subject variability, which is the result of the vari-
ability in the same subject over time, and between-
subject variability, which due to heterogeneous 
physiology among subjects (8). For accurate inter-
pretation of patient vWF and ADAMTS13 test re-
sults, the biological variation associated with these 
assays must be determined. In the present study, 
we aimed to investigate the biological variation of 
ADAMTS13 antigenicity and activity for the first 
time. We also measured the biological variations 
of vWF antigenicity and activity which have shown 
heterogeneity in the results in earlier studies (8-11). 
Additionally, the reference change value (RCV) and 
index of individuality (II) for both vWF and AD-
AMTS13 antigenicity and activity were calculated.
Materials and methods
Subjects
This study was conducted at the Acibadem 
Labmed Clinical Laboratories in Istanbul, Turkey. 
The study protocol was approved by the Ethical 
Committee of Acibadem University. All partici-
pants signed informed consent. A total of 19 sub-
jects (10 male, 9 female) with a mean age of 30 
years (range 21–40) were recruited to estimate the 
biological variations of vWF and ADAMTS13 anti-
genicity and activity. Different number of samples 
were used for vWF (19 samples) and ADAMTS13 
antigenicity (16 samples) and activity (15 samples). 
The subjects were apparently healthy and did not 
have a history of bleeding disorders, pregnancy, 
drug abuse or medical prescription.
Methods
Fasting venous blood samples were collected 
weekly between 8 and 10 am on the same day for 
5 consecutive weeks. All subjects were in a sitting 
position, and 2 mL of blood samples were collect-
ed (in BD Vacutainer tube, containing Na3-citrate 
as anticoagulant, Plymouth, UK) after 10 min of 
rest by a single phlebotomist. All blood samples 
were transported to the laboratory under identical 
conditions in terms of temperature and elapsed 
time. All samples were centrifuged at 1500 × g for 
10 min and the plasma was aliquoted and stored 
at -80 ºC until analysis. ADAMTS13 antigenicity and 
activity were determined using ELISA methods as 
described by the manufacturer (Technoclone 
GmbH, Vienna, Austria). According to the data giv-
en by the manufacturer, the detection limit of the 
ADAMTS13 antigenicity assay was 0.02 µg/mL, 
while that of the activity assay was 0.2%. The vWF 
antigenicity was determined by an immunotur-
bidimetric method (Diagnostica Stago, Asnieres 
sur Seine, France). vWF activity was determined 
using the ristocetin cofactor assay (RICOF) with op-
tical-turbidimetric detection (CHRONO-LOG Lumi 
Aggregometer, PA, USA). We used the same lot of 
reagents. According to the data given by the man-
ufacturer, the detection limits of vWF antigenicity 
and activity were both 1.0%. For internal quality 
control (QC), we routinely use commercially avail-
able QC samples to calculate the analytical varia-
tion (CVA) of high and low level of ADAMTS13/vWF 
antigenicity and activity. The result of internal QC 
data was within acceptable range. Due to matrix 
problem, we preferred patients’ samples instead 
of commercially available QC samples. For each 
method, we selected a patient plasma sample ran-
domly and measured the tests several times in the 
same run to calculate within-run CVA.
Statistical analysis
Data were analyzed for the presence of outliers us-
ing Grubbers’ test. Modified Levene Test was used 
for homogeneity of variances. We used nested 
analysis of variance (nested ANOVA) to calculate 
the total within- and total between-subject varia-
tions using inter-individual values for between-
subjects and inter-week values for within-subjects. 
P-values < 0.05 were considered to indicate statis-
tical significance. The biological component varia-
tion for each test was then determined by sub-
tracting the CVA from the total within-subject and 
total-between subject variations as given below 
(12):
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     CVT = (CVB2 + CVA2)1/2 
Where CVT is the total coefficient of variation, CVB 
is the biological coefficient of variation, and CVA is 
the analytical coefficient of variation.
Biological coefficient of variation can be obtained 
as:
CVB = (CVT2 - CVA2)1/2
We calculated the index of individuality (II) using 
the method described by Fraser (7) as follows:
II = (CVA2 + CVI2)1/2 / CVG
where CVW is the within-subject biological coeffi-
cient of variation and CVG is the between-subject 
biological coefficient of variation.
Calculating II is usually simplified to the following 
equation:
II = CVW / CVG
Finally, we calculated RCV using the method de-
scribed by Fraser (12) as follows:
RCV = 21/2 x Z x (CVW2 + CVA2)1/2
Where Z is a constant, depending on the probabil-
ity and most often 1.96 is used as significant, that 
is, P < 0.05.
Results
Tables 1 and 2 show the main findings of this study. 
Table 1 shows the total variation (biological and 
analytical) for each test. As shown in table 2, the 
within-subject biological variations of vWF activity 
and antigenicity were lower than the between-
subject biological variations. However, the within-
subject biological variations of ADAMTS13 activity 
and antigenicity were higher than the between-
subject biological variations. The II of vWF activity 
(0.44) and antigenicity (0.64) were lower than that 
of ADAMTS13 activity (1.32) and antigenicity (1.55).
The mean and absolute range of vWF and AD-
AMTS13 antigenicity and activity are shown in fig-
ures 1 and 2, respectively. The range of vWF anti-
genicity and activity values shows that individual 
variation accounts for only a small portal of the to-
tal dispersion for all subjects (Figure 1). The range 
of subject values for ADAMTS13 antigenicity and 
activity was not as varied as that of vWF antigenic-
ity (Figure 2). Statistically, there was an outlier in 
ADAMTS13 antigen group and we excluded the 
data of this subject from the study. The dispersion 
of vWF antigenicity values was similar to vWF ac-
tivity, while ADAMTS13 antigenicity was also found 
to be similar to activity. The RCV of vWF antigenic-
ity was higher than the activity RCV (41.01% versus 
29.77%) (Table 2). However, the RCV of ADAMTS13 
antigenicity and activity were similar at 36.15% 
and 37.14%, respectively.
Discussion
The present study shows for the first time that AD-
AMTS13 antigenicity and activity have high within- 
and between-individual biological variation, but 
low individuality. In the daily practice of clinical 
testing, biological variation is critical to patient di-
agnosis and monitoring. Diagnosis requires the 
use of reference intervals, while condition moni-
toring relies on the analysis of consecutive test re-
sults. 
We compare patient test results to the reference 
interval, a value accepted as normal. The reference 
interval is obtained from apparently healthy popu-
lations served in the region, and is therefore re-
ferred to as a population-based reference interval. 
In general, at least 120 reference subjects are ran-
domly selected from the population, according to 
the criteria of the IFCC (International Federation of 
Clinical Chemistry and Laboratory Medicine) and 
CLSI (Clinical and Laboratory Standards Institute), 
and test results are used to determine the refer-
ence interval (13,14).
A population-based reference interval is not an 
ideal tool for interpreting patient results, particu-
larly in the case of diagnosis. Due to individuality, 
the data obtained from some healthy individuals 
may be outside of the reference interval. To evalu-
ate the effect of individuality, II is determined. As 
given in the equation 4, the ratio of CVW to be-
tween CVG is used for II calculation. II values great-
er than 1.4 indicate that the analyte has little indi-
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(N = 19) 10.75 19.83 7.11
vWF antigen
(N = 19) 14.63 22.87 3.57
ADAMTS13 activity
(N = 15) 13.40 10.51 4.21
ADAMTS13 antigen
(N = 16) 13.05 10.70 8.66
Within- and between subject total variations are the sum of within- and between-subject biological and analytical 
variations respectively, CV – coefficient of variation.
Table 1. Total variation (biological and analytical) for each test.








(N = 19) 8.06 18.5 29.77 0.44
vWF antigen
(N = 19) 14.37 22.59 41.01 0.64
ADAMTS13 activity
(N = 15) 12.73 9.63 37.14 1.32
ADAMTS13 antigen
(N = 16) 9.75 6.28 36.15 1.55
Within- and between-subject biological variations are derived by subtracting the CVA from the total within- and between-subject 
variations respectively.
Table 2. Biological variation, RCV and II for each test.
with marked individuality (12,15). Comparison of 
the test result with the population-based refer-
ence interval is a satisfactory practice only for ana-
lytes with the index of individuality higher than 1, 
with the highest sensitivity for index values higher 
than 1.4. An II test value below 1.0, particularly less 
than 0.6, indicates it is not appropriate to use the 
population-based references interval, while an II 
value higher than 1.4 indicates a population-based 
reference interval can be safely applied (16).
This study found the II value of ADAMTS13 activity 
to be 1.32 and 1.55 for ADAMTS13 antigenicity. 
These results indicate ADAMTS13 antigenicity and 
activity exhibit little individuality. We were not 
able to find data in the literature related to the bio-
logical variation and II of ADAMTS13 while prepar-
ing this manuscript, and were therefore unable to 
compare our data to previous findings.
Unlike ADAMTS, the biological variation of vWF 
has been studied. Various data for vWF have been 
reported, depending on the population studied. 
Indeed, genetic factors have been found to highly 
influence plasma vWF levels (17). vWF levels also 
increase with age and may be 25% lower in indi-
viduals whose blood group is O (18,19). As shown 
in Figure 1A and B, visually, vWF levels seems to be 
lover in individuals whose blood group is O in 
comparison to other groups. As far as we know, bi-
ological variations of vWF, based on subjects’ 
blood groups, have not been studied.
In the literature, the number of subjects, duration 
of studies and time interval between consecutive 
sampling of biological variation studies shows 
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Figure 1a and B . The mean and absolute range of vWF antigen and activity in human adults (1-10: men; 10-19: women). The subjects 
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Figure 2a and B . The mean and absolute range of ADAMTS13 antigen (1-8: women; men; 9-16: men) and activity (1-8: men; women; 
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great variability and has not been standardized. In 
our study we collected samples weekly for 5 con-
secutive weeks. However, Thompson et al. (10) fol-
lowed 14 subjects (6 male and 8 female) for 3 years 
and made 20 measurements. Thompson et al. (10) 
reported the within- and between-subject biolog-
ical variations of vWF antigenicity to be 28% and 
71%, respectively. The database of biological varia-
tion reported the within- and between-subject bi-
ological variations of vWF activity to be 2.5% and 
27.5%, respectively (20). Similarly, this database 
documented the within- and between-subject bi-
ological variations of vWF antigenicity as 5.0% and 
18.0%, respectively (20).
The values obtained from the database were used 
to calculate the IIs of vWF activity (0.09) and anti-
genicity (0.28). The II of vWF antigenicity reported 
by Thompson et al. (10) was 0.39. We determined 
the II to be 0.44 for activity and 0.64 for antigenici-
ty. Since the II of both vWF antigenicity and activi-
ty were low, we speculate that vWF results exhibit 
marked individuality. This suggests that an indi-
vidual can have a unique vWF activity value out-
side the range of other individuals. It means that 
the worldwide used practice for comparing each 
test result with the corresponding population-
based reference interval is not suitable in case of 
marked individuality of the analyte. Instead, com-
parison of the current test result in relation to the 
previous result is likely to be better approach for 
interpretation of the test result. Consequently, the 
population-based reference interval may not be 
adequate for the interpretation of patient results 
and the vWF reference intervals should be re-eval-
uated for subgroups.
In the literature we can find data related to biolog-
ical variation of many tests and we do not need to 
evaluate the components of biological variation 
for all analytes in our laboratory. However the data 
available in the literature are not homogenous 
and, as shown in vWF, for the same test we can 
find different results. To overcome the heteroge-
neity problem we need to standardize the pre-an-
alytical influences and use correct statistical tests. 
Recently Røraas T. et al. (21), published an impor-
tant paper related to the study design of biologi-
cal variation to obtain reliable data. Pre-analytical 
variables, particularly those that are controllable, 
such as posture, exercise, smoking and so on 
should be standardized prior to biological varia-
tion studies. For this purpose we need a guideline 
to standardize the pre-analytical variables. Addi-
tionally, meta-analysis may be required to obtain 
reliable data of biological variation for clinical prac-
tice.
RCV is particularly important for monitoring pa-
tients, where it is used to interpret the difference 
between two consecutive test results. As shown in 
the equation 5, data on within-subject biological 
variation and analytical precision can be used to 
determine the significant change of two serial re-
sults while for assessing the utility of population-
based reference intervals. If the difference be-
tween two consecutive results is less than the RCV, 
the result is not statistically significant. Therefore, 
the difference between two consecutive results 
should not necessarily be interpreted as the result 
of a therapy. RCV value is crucial in the evaluation 
of therapeutic effects. For example, a difference 
between two consecutive ADAMTS13 activity mea-
surements of less than 37.14% (Table 2) means that 
the difference may be due to random oscillation 
rather than the result of a significant change. To 
calculate the RCV, both the analytical and biologi-
cal variation must be known. Biological variation 
may be documented in the literature if it has been 
studied, while analytical variation is unique to the 
equipment and reagents of the laboratory in ques-
tion. For this reason, each laboratory should deter-
mine the RCV for each test. Here we calculated the 
RCV of each test using the data in tables 1 (analyti-
cal variation) and 2 (within-subject biological vari-
ation), as described by Fraser (16).
There are some limitations to this study. Some in-
fluences such as age, race, sex, blood groups are 
important factors in biological variation studies. 
As shown in Figure 1A and B, vWF levels seem to 
be lower in individuals whose blood group is O (18, 
19). In our study we did not calculate the biological 
variation for subgroups such as age, sex and differ-
ent blood groups. The statistic of small group is 
not reliable and we need large number subjects to 
determine biological variation of vWF and AD-
AMTS13 for subgroups. Additionally, the duration 
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of our study is 5 weeks and consecutive measure-
ment within a long period including large number 
subjects might be needed for more accurate data.
In conclusion, ADAMTS13 antigenicity and activity 
displayed high between- and within-subject bio-
logical variations, but low individuality. Similarly, 
vWF antigenicity and activity exhibited high be-
tween- and within-subject biological variations, 
but high individuality. Population-based reference 
intervals may be useful for monitoring ADAMTS13 
antigenicity and activity, but not for vWF, which 
displays high individuality.
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